for people ages 18-99 (full criteria)
at San Francisco, California and other locations
study started
estimated completion



This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

Official Title

Uptravi® (SelexiPag): tHe usErs dRug rEgistry


Pulmonary Arterial Hypertension Hypertension Familial Primary Pulmonary Hypertension Selexipag


You can join if…

Open to people ages 18-99

  • Signed patient informed consent form (ICF).
  • Patients ≥ 18 years of age at time of Uptravi initiation, and
  • Patients who initiate Uptravi:
  • at enrollment, or
  • less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)

You CAN'T join if...

  • Patients previously exposed to Uptravi treatment during a clinical trial.
  • Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
  • Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.


  • UCSF Medical Center accepting new patients
    San Francisco California 94143 United States
  • Santa Barbara Cottage Hospital accepting new patients
    Santa Barbara California 93105 United States


accepting new patients
Start Date
Completion Date
Study Type
Observational [Patient Registry]
Last Updated